A wider view of drug development in Japan

Wednesday, Nov. 18, 2026 | 11 a.m. - 1 p.m. ET

Drug developers come to Japan with different questions. How the work gets funded. How a product reaches the market. How a company gets started. Who to build with on the science side.

Japan has expanded support and infrastructure on each of these fronts. The PMDA has opened an office in Washington, DC. Funding programs are structured to double venture investment in eligible biotechs. The FY2026 pricing revision has taken effect, with parts of the agenda still open.

Endpoints News and Nikkei Biotechnology & Business bring senior regulators, company leaders and investors together to work through where the reforms stand — alongside financing, commercialization, startup formation and the partnerships connecting Japanese science and global biopharma. Join us.

SPONSORED BY